Not rendering correctly? View this email as a web page here.

- June 2018 -


FAST Spring 2018 Closing Showcase Celebrates Six Companies

Read More


  • The 2018 CA JumpStart Grant opens this August | Read Here 
  • Sandstone Diagnostics (FAST Fall 2013) presented results of digital male fertility risk assessment algorithm with men trying to conceive | Read More
  • Ligandal (FAST Spring 2016) successfully used a ligand-targeted nanoparticle to deliver CRISPR into the nucleus of a T-cell | Read More
  • FDA launches innovation challenge to spur development of medical devices – including digital health and diagnostics – that target pain, addiction and diversion | Read More

About FAST Advisory Program

The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.

For information on the FAST program, contact Julie Harness at

Upcoming Events & Key Dates
6/19 CLSI Innovation Series: How to Find the Right Lab Space for your Startup South San Francisco, CA Register Here
6/19 SVHealth Monthly Meetup – Networking, StartUps and Keynote by Ruchita Sinha, Sunnyvale, CA Register Here
6/20 5th Annual Rosenman Symposium, UCSF Mission Bay Register Here
6/20 FOCIS 2018, San Francisco, Register Here
6/21 UC Berkeley Skydeck Angel Investor Panel, Berkeley, CA. Contact Bree Cahill for more info:
6/23 CABS BioPacific Conference: Innovation, Collaboration, and Globalization, San Mateo, CA Register Here
6/27 Up and Out - Tips on navigating life science relocation, JLabs, South San Francisco Register Here
7/10 FAST & Fellows Networking Happy Hour, South San Francisco, CA Invitation Only: Email
7/11 CLSA’s 3rd Anniversary Celebration & San Diego Open House, San Diego, CA Register Here
7/16 New Funding Source: YC Bio, San Francisco, CA Register Here
7/20 Applications for CLSI’s FAST Fall 2018 due. Apply Here
7/23-26 ISS R&D Conference 2018 (Use registration type CLSA) Register Here
9/20 The Secret Science of Storytelling, JLabs, South San Francisco Register Here
10/4 Intro to Immunogenicity: Keys to Safe and Effective Drug Development, JLabs, South San Francisco Register Here



  • CARB-X announced that the UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, and other products against drug-resistant bacterial infections. GAMRIF and BMGF have committed an aggregate of up to $52M over the next three years | Read More
  • Powered by CARB-X company Melinta Therapeutics launched a new antibiotic stewardship program to fight against the global health threat of antimicrobial resistance | Read More
  • CARB-X awards up to $8.6 million to California-based company Talis Biomedical to support the development of its molecular diagnostic system to speed diagnosis and appropriate treatment of chlamydia and gonorrhea, including drug-resistant infections | Read More
  • CARB-X awards up to $3.5 million to California-based company MicrobeDx to support the development of its rapid diagnostic system for potentially life-threatening infections in the urinary tract | Read More
  • Powered by CARB-X company Entasis Therapeutics announced initiation of clinical studies of novel oral beta-lactamase inhibitor ETX0282 | Read More
  • Powered by CARB-X company Spero Therapeutics announced positive top-line data for two product candidates from its potentiator platform | Read More. Spero also awarded a £250K grant to the University of Liverpool to help develop new antibiotic SPR206 | Read More
  • Powered by CARB-X company T2 Biosystems received FDA clearance to market T2Bacteria Panel for detection of sepsis-causing pathogens | Read More.
    T2 Biosystems also announced closing of a $52.6M public offering | Read More
  • Powered by CARB-X company Tetraphase Pharmaceuticals announced that Everest Medicines, a biopharmaceutical company in China - which has the exclusive license to develop and commercialize eravacycline in China, Taiwan, Hong Kong, Macau, South Korea, and Singapore - submitted an IND to China’s Food and Drug Administration (CFDA) for a phase 3 clinical trial of eravacycline in complicated intra-abdominal infections. Tetraphase’s eravacycline NDA is under review in the U.S. | Read More

Other AMR News

  • The FDA gives BacterioScan clearance to market its rapid automated diagnostic system, 216Dx, for detection of bacterial urinary tract infections (UTIs) | Read More
  • NIAID release a new Broad Agency Announcement (BAA) requesting proposals for therapeutics and vaccine development contracts: emphasis on funding efforts to combat antibiotic-resistant bacteria, among other pathogens of high-priority for both BioD and public health indications | Learn More
  • UK government has announced investing over £30 million to the global fight against antimicrobial resistance, £20 million to CARB-X, £5 million towards partnership with Argentina by the National Scientific and Technical Research Council (CONICET), £5 million invested in the Foundation for Innovative New Diagnostics (FIND), and £1 million invested in the Global Antibiotic Research and Development Partnership (GARDP) | Read More
  • Insights on whole genome sequencing for the use of initiating countermeasures against the emergence and spread of antibiotic-resistant bacterial pathogens | Read More
  • WHO published its first Essential Diagnostics List, to improve diagnosis and treatment outcomes for the most common conditions as well as a number of global priority diseases | Read More
  • A team at Tufts University School of Medicine published research on insights on a specific molecular network that could expose new targets for drug-resistant infections | Read More
  • The Quave Rearch Group at Emory University and a research group from Georgia Tech have received NIH/NIAID funding for their project on “Novel compounds from botanical innovation yields Acinetobacter treatments” | Read More
  • Why new antibiotics are so hard to find – this article uses helpful analogies to enable readers to visualize the technical challenges researchers face in targeting bacterial pathogens and defending against their resistance mechanisms | Read More
  • PLOS One announced the launch of the Antimicrobial Resistance Channel, which will highlight research from across the four pillars of AMR research: basic science, research and development, appropriate use and access, and surveillance and epidemiology | Read More

 About CARB-X


CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With more than $500 million to invest, CARB-X funds the best science from around the world. The CARB-X portfolio is the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent and treat life-threatening bacterial infections. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI).

For more information on CARB-X, please contact Amy Xu at

Upcoming Events
6/14 Duke-Margolis & FDA event – important public meeting focused on Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics Register Here
6/17 Abstract submission deadline for Averting the post-antibiotic era – challenges and developments conference, Denmark Apply Here. Registration fee, accommodation and local costs for all approved applicants are covered by the Novo Nordisk Foundation
6/22-26 5th International One Health Congress Track 3: Antimicrobial Agents and Resistance Saskatoon, Canada More Info and Register Here
6/27 DA Workshop on inhaled antibacterial drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis, Washington DC Register Here
7/16-20 Short course | AMR: a multidisciplinary approach, London, UK More Info and Apply Here
7/22-27 Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture, Smithfield, RI Register Here
8/21-22 NIAID-NINDS-DTRA Workshop – Infectious Disease in the CNS and Therapeutic Strategies to Cross the Blood-Brain Barrier, Rockville, MD Register Here
9/4-7 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal Register Here


 STEM Education & Careers 

  • CLSI & Biocom Institute release the 2018 California Life Science Workforce Trends Report | Read More
  • CLSI’s Amgen Bay Area BioGENEius, Shloka Janapaty, received the Honorable Mention Award in the International Global Environmental Challenge at the 2018 BIO International Convention for her research on novel plastics remediation process | Read Here
  • KNBR, the California Life Sciences Association (CLSA) and the California Life Sciences Institute (CLSI) announce the second annual Giants of Science grant competition, an opportunity for high schools to win $20,000 for their science program. Application deadline July 31 | Read More
  • Bio-Link Equipment Depot Open House at Foothill College June 16 | Get Tickets
  • Biotech Primer Article: Immunotherapy Goes Viral | Read More
  • Biotech Primer Article: Taking a Swing at Peanut Allergies | Read More
  • Biotech Primer Article: CRISPR’s Genome Detectives | Read More
  • Biotech Primer Article: Groundbreaking! Migraine Drug Explained | Read More

About CLSI Education & Career Programs

CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.

Upcoming Events
6/16 Bio-Link Equipment Depot Open House at Foothill College Get Tickets
6/20 Understanding Drug Pricing And Reimbursement, South San Francisco, CA Register Here
6/20 Bay Area Council: Veterans Employer Summit, San Francisco, CA Register Here
9/20-21 BioBasics: Biotech For The Non-Scientist, South San Francisco, CA Register Here
 10/11-12  Biotech Primer: Drug Development Immersion, South San Francisco, CA Register Here



California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.

CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.